Several techniques can be used to diagnose
Introduction
Charcot-Marie-Tooth disease type 1A (CMT1A) and hereditary neuropathy with liability to pressure palsies (HNPP) are the two most common peripheral neuropathies. 1 By a gene dosage mechanism, CMT1A and HNPP result from duplication or deletion, respectively, of a 1.5 Mb DNA fragment on chromosome 17p12 that contains the peripheral myelin protein 22 (PMP22) gene. Compared with two copies in normal people, the PMP22 gene has been shown to be amplified to three or even four copies in CMT1A cases and deleted to one copy in HNPP. 2, 3 Several techniques can be used for the molecular diagnosis of CMT1A and HNPP. Most of these methods rely on dosage analysis, using either DNA probes that detect restriction fragment length polymorphisms (RFLPs) 4, 5 or, more recently, polymerase chain reaction (PCR)-based microsatellite
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Comparison of methods to diagnose PMP22 gene polymorphisms markers from within the duplicated region. 6 The use of fluorescent in situ hybridization (FISH) to visualize directly the number of PMP22 gene copies on interphase chromosomes has also been documented. 7 Pulsed-field gel electrophoresis (PFGE) can be used to examine the entire 1.5 Mb region. 8 Further definition of the 'hotspot' region in the PMP22 gene has revealed proximal and distal CMT1A repetitive element (REP)-specific restriction sites leading to the development of Southern blot probes, 9 and more, recently, PCR-based tests. 10 The main drawbacks of these methods are that they are labour intensive, expensive and have limited sensitivity, which makes them difficult to use for routine diagnostic testing.
Multiplex ligation-dependent probe amplification (MLPA) was reported to be able accurately to detect variations in the numbers of copies of sections of the human genome. 11 The aim of this study was, therefore, to compare MLPA with existing FISH and RFLP-PCR methods in a set of cases referred for CMT1A or HNPP genetic testing.
Materials and methods

SAMPLES
Peripheral whole blood samples sent to the Laboratory of Medical Genetics (University Clinical Centre Maribor) for CMT1A and HNPP testing were included in this observational study. DNA was isolated by a simple in-house salting-out procedure, 12 then the samples were coded and distributed for testing.
FLUORESCENT IN SITU HYBRIDIZATION MAPPING
The interphase chromosome FISH procedure was performed on cultured lymphocytes freshly isolated from the peripheral whole blood samples. Informed consent was obtained from patients for additional tests using new methods to be carried out on the samples. The nature of the study meant that ethical review was not required.
Slides for FISH were prepared by standard cytogenetic protocols and pre-treated with pepsin to optimize hybridization. Singlecolour FISH was carried out as previously described. 7 A PAC RP-1004H15 DNA probe (provided by Professor Mariano Rocchi, University of Bari, Bari, Italy), which spans the smallest duplication region and includes the PMP22 gene, was isolated from a cultivated bacterial clone with a HiSpeed TM Plasmid Purification Kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. The DNA probe was labelled with digoxigenin (Boehringer Ingleheim, Ingleheim, Germany) by nick translation, as described previously. 13 Cells were scored in a blinded fashion by at least two analysts who had no knowledge of the origin of the specimen, on a 100 nuclei per analyst per sample basis.
DETECTION OF CMT1A DUPLICATION BY RFLP-PCR
Two primers were used for RFLP-PCR detection of the CMT1A duplication. The upstream primer A was 5′-GGAGCCCTCAATCAGT GGAA-3′ (distal CMT1A-REP bases 1785 -1806), and the downstream common primer C was 5′-ACAAGAGTTCAAGTAACTTGC-3′ (distal CMT1A-REP bases 3751 -3771) (GenBank No. 41165). The PCR conditions were as described previously, 9 except that the annealing temperature used in the present study was 63°C. Amplified DNA fragments were digested with the Mph1103I restriction enzyme according to the manufacturer's instructions (Fermentas Life Sciences, Glen Burnie, MD, USA), electrophoresed on a 1.5% agarose gel and visualized with SYBR ® Green I nucleic acid gel stain (Fluka, SigmaAldrich, Steinheim, Germany).
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Multiplex ligation-dependent probe amplification was performed using the commercial SALSA P033 CMT1/HNPP region MLPA ® kit (MRC-Holland, Amsterdam, The Netherlands) according to the manufacturer's instructions. Samples amplified with one Cy5.0-labelled and one unlabelled primer were analysed on a CEQ™ 8000 genetic analysis capillary electro phoresis system (Beckman Coulter, Fullerton, CA, USA). For each sample, both quantitative analysis and quality control were carried out. For results in uncertain ranges, the MLPA tests were repeated.
Quantitative analysis
Excel software was used to record peak areas corresponding to the signal from each probe. In order to produce normalized ratios reflecting the relative probe dosage, each peak area was divided by the sum of all peaks. For each probe, this ratio was divided by the same ratio from an unaffected control run in the same experiment. Expected normalized values were 1.0 in the absence of any change in copy number, and 0.5 or 1.5 in the case of a heterozygous deletion or duplication, respectively.
Quality control
The Beckman CEQ™ 8000 Reference Guide (Beckman Coulter) states that best results are obtained if the fluorescent signals range between approximately 15 000 and 150 000 relative fluorescent units (RFU). In this study, it was shown that reproducible results were obtained when all peak heights were > 5000 RFU. Peaks were considered unreliable if they were outside the predefined threshold range of 5000 -150 000 RFU.
Results
A total of 70 peripheral blood samples from a mixture of fully and partially characterized cases, as well as from cases in which no mutations had been found, were screened in a semi-blind manner (Table 1) . Of the 28 mutations (nine duplications and 19 deletions) found in the 70 samples and previously characterized in the Laboratory of Medical Genetics (University Clinical Centre Maribor) using FISH and RFLP-PCR, all were detected using the MLPA technique (Table 1) .
After carrying out the interphase chromosome FISH procedure, each analyst counted 100 interphase nuclei (number of two and three signals) per sample, recording the number of signals: if two signals were detected in ≥ 70% of the counted cells then it was considered that there were no duplications; if there were three signals in ≥ 70% of counted cells then it was considered that a duplication of the CMT region was present (Fig. 1) .
The RFLP-PCR analysis of the recombination 'hotspot' in the REP regions of the CMT1A locus obtained some discordant results compared with the FISH and MLPA analyses: one duplication detected using FISH and MLPA had a false-negative RFLP-PCR result; three results that were negative for duplications using FISH and MLPA showed as false-positives with RFLP-PCR ( Table 1) .
Discussion
With currently available technology, the molecular genetic diagnosis of CMT1A and HNPP still remains a labour intensive and costly procedure. When specific precautions are taken, quantitative RFLP-PCR is able to detect deletions and/or duplications, but it is laborious and difficult to implement on a routine basis. The interphase chromosome FISH procedure is a qualitative approach to testing and is the preferred technique in cytogenetics laboratories. 7 Our own 
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experience has shown that FISH analysis for CMT1A is technically and analytically demanding, while the probes are not commercially available and their preparation requires in-house validation and quality control. Analysis is subjective and requires experience to distinguish genuine duplication signals from replication signals. There is, therefore, an obvious need for a simple, accurate and less expensive laboratory test.
The MLPA technique is a new method for the measurement of gene copy number that, from our experience, offers great promise for the detection of gene dosage abnormalities in a wide range of conditions. It relies on comparative quantitation of specifically bound probes that are amplified by PCR using universal primers. The introduction of universal primers has advantages in that multiplexing numerous targets becomes much easier and fluorescence detection of the products requires only one fluorescent primer, thereby reducing the cost compared with buying fluorescent probes for each target. The MLPA technique was used in the present study to test for CMT1A and HNPP and was compared with existing interphase chromosome FISH and RFLP-PCR methods. The results showed 100% concordance between the FISH and MLPA techniques for the 70 samples tested, of which 28 had duplications or deletions.
One false-negative and three falsepositive PCR results were obtained using RFLP-PCR analysis of the recombination 'hotspot' in the REP regions of the CMT1A locus. False-negative results can be expected in about 20% of PMP22 duplications, which are thought to have breaking points of the recombination event outside the usual 'hotspot'. 9 Possible explanations for the false-positives include: unknown polymorphisms present in the REP regions; insufficient allele specificity of the PCR amplification to distinguish distal from proximal REP elements; or genetic conversion between proximal and distal REPs. In addition, samples from patients who are mosaics for PMP22 gene duplication should also be subjected to the RFLP-PCR test for recombination event positivity because an intermediate or inconclusive result from MLPA and FISH analysis might be expected in mosaic patients.
The main advantages of the MLPA approach over FISH and RFLP-PCR are its relative simplicity and speed. Although 80% of duplications can be detected using RFLP-PCR, the breakpoints are often not determined and rare mutations outside the 'hotspots' will be missed. In contrast to many other methods, the MLPA technique should be easy to implement in a standard diagnostic laboratory, since no new technology needs to be introduced. The critical phases are hybridization and PCR, and the products can be analysed on any apparatus that is used for sequence analysis. Furthermore, it can easily be applied to any (disease) gene of interest, and the resolution and potential for array implementation may even allow future genome-wide screening.
Polymorphisms or single-base mutations in the probe binding regions may affect the MLPA results. The short length of the specific probe region in the MLPA probes means that nucleotide mismatches at the probe binding site may influence probe hybridization, prevent ligation and affect detection, so that single base changes may appear as exon deletions. For this reason, we recommend that all simple fragment deletions found by MLPA should be confirmed by an independent method, and that sequencing of the target region be undertaken should an independent test not indicate deletion. The power of MLPA detection will also be weakened by mosaicism; e.g. if the PMP22
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Comparison of methods to diagnose PMP22 gene polymorphisms duplication was present in only 20% of analysed cells, then it is likely that the duplication would go undetected by MLPA. This would, however, also be a problem for many other methods that rely on DNA dosage to detect deletions and duplications. As a result of this limitation, it may be necessary to have at least two independent methods, for example MLPA in combination with FISH, with the latter able to detect mosaic cases.
In conclusion, MLPA is a simple, fast, sufficiently sensitive and sequence-specific test for detection of PMP22 gene duplications/deletions in the molecular diagnosis of CMT1A and HNPP.
